Table 3.
Treatment | Dose/route | Mean paw volume before carrageenan injection | Increase in paw volume (ml) after carrageenan injection (Mean ± SD)/Percent inhibition of edema | |||
---|---|---|---|---|---|---|
+1 h | +2 h | +3 h | +4 h | |||
Saline | 2 ml, i.p. | 1.12 ± 0.08 | 2.58 ± 0.09 | 2.67 ± 0.09 | 2.21 ± 0.09 | 1.81 ± 0.11 |
FXM | 100 mg/kg, p.o. | 1.11 ± 0.08 | 2.52 ± 0.06 | 2.30 ± 0.09 | 2.12 ± 0.20 | 1.48 ± 0.08 |
5.88 ± 1.99c | 19.72 ± 2.39cde | 35.84 ± 12.89cd | 45.28 ± 4.02bc | |||
FXM | 200 mg/kg, p.o. | 1.17 ± 0.09 | 2.44 ± 0.04 | 2.05 ± 0.06 | 1.92 ± 0.04 | 1.45 ± 0.06 |
15.34 ± 7.95b | 41.07 ± 5.00b | 52.51 ± 8.30b | 58.52 ± 8.19b | |||
FXH | 100 mg/kg, p.o. | 1.15 ± 0.08 | 2.61 ± 0.08 | 2.56 ± 0.09 | 2.51 ± 0.11 | 1.71 ± 0.08 |
2.84 ± 2.42c | 4.99 ± 3.22g | 13.44 ± 5.41e | 18.81 ± 2.21e | |||
FXH | 200 mg/kg, p.o. | 1.11 ± 0.05 | 2.55 ± 0.05 | 2.33 ± 0.06 | 2.32 ± 0.05 | 1.61 ± 0.04 |
3.96 ± 2.28c | 17.89 ± 2.03de | 23.29 ± 4.53de | 27.88 ± 6.75de | |||
FXC | 100 mg/kg, p.o. | 1.14 ± 0.06 | 2.58 ± 0.06 | 2.21 ± 0.06 | 2.06 ± 0.13 | 1.53 ± 0.08 |
3.85 ± 1.85c | 28.28 ± 3.11c | 42.12 ± 7.49bc | 43.57 ± 5.21bc | |||
FXC | 200 mg/kg, p.o. | 1.09 ± 0.04 | 2.17 ± 0.04 | 1.71 ± 0.03 | 1.53 ± 0.04 | 1.25 ± 0.04 |
29.19 ± 4.60a | 59.67 ± 3.23a | 73.29 ± 2.65a | 77.64 ± 3.04a | |||
FXE | 100 mg/kg, p.o. | 1.12 ± 0.07 | 2.59 ± 0.06 | 2.47 ± 0.04 | 2.34 ± 0.06 | 1.55 ± 0.08 |
1.71 ± 0.82c | 8.76 ± 3.66fg | 22.32 ± 6.02de | 36.22 ± 8.23cd | |||
FXE | 200 mg/kg, p.o. | 1.12 ± 0.06 | 2.56 ± 0.07 | 2.25 ± 0.05 | 2.18 ± 0.05 | 1.49 ± 0.05 |
4.08 ± 1.78c | 23.60 ± 2.10cd | 32.38 ± 4.66cd | 45.77 ± 4.22bc | |||
FXB | 100 mg/kg, p.o. | 1.11 ± 0.06 | 2.59 ± 0.04 | 2.50 ± 0.05 | 2.32 ± 0.07 | 1.62 ± 0.07 |
1.49 ± 1.71c | 6.25 ± 1.15fg | 23.07 ± 4.45de | 25.68 ± 3.08de | |||
FXB | 200 mg/kg, p.o. | 1.11 ± 0.06 | 2.55 ± 0.07 | 2.30 ± 0.06 | 2.19 ± 0.08 | 1.52 ± 0.06 |
3.63 ± 1.31c | 19.84 ± 3.34cde | 31.08 ± 5.33cd | 39.89 ± 7.36cd | |||
FXA | 100 mg/kg, p.o. | 1.10 ± 0.06 | 2.58 ± 0.06 | 2.48 ± 0.09 | 2.50 ± 0.08 | 1.70 ± 0.05 |
1.60 ± 1.16c | 7.05 ± 2.71fg | 11.17 ± 2.82e | 13.18 ± 3.04e | |||
FXA | 200 mg/kg, p.o. | 1.12 ± 0.06 | 2.59 ± 0.05 | 2.39 ± 0.04 | 2.36 ± 0.07 | 1.63 ± 0.01 |
1.82 ± 1.64c | 14.47 ± 4.31ef | 20.80 ± 2.55de | 24.94 ± 7.76de | |||
Diclofenac sodium | 10 mg/kg, i.p. | 1.13 ± 0.08 | 2.57 ± 0.05 | 1.63 ± 0.05 | 1.46 ± 0.08 | 1.24 ± 0.04 |
4.08 ± 2.47c | 67.32 ± 4.25a | 80.54 ± 2.61a | 85.23 ± 7.71a |
FXM F. xanthoxyloides methanol extract, FXH F. xanthoxyloides n-hexanefraction, FXC F. xanthoxyloides chloroform fraction, FXE F. xanthoxyloides ethyl acetate fraction, FXB F. xanthoxyloides n-butanol fraction, FXA F. xanthoxyloides residual aqueous fraction. Data values shown represent mean ± SD (n = 6). One-way ANOVA followed by Tukey’s HSD multiple comparison tests. Percentage inhibition is shown in brackets. Different superscript alphabets in each column indicate difference at P <0.05